Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population

AIDS

Volumn 14, Issue 11, 2000, Pages 1545-1552

  Mocroft, Amanda ^a   Devereux, Helen ^a   Kinloch De Loes, Sabine ^a   Wilson, Debbie ^a   Madge, Sara ^a   Youle, Michael ^a   Tyrer, Mervyn ^a   Loveday, Clive ^a   Phillips, Andrew N ^a   Johnson, Margaret A ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

Clinical outcome; HAART; Highly active antiretroviral therapy; Immunologial outcome; Virological outcome

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RATE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0033811217     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00010     Document Type: Article

References (32)

1. Changing patterns of mortality across Europe in patients infected with HIV
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
4. Impact of protease inhibitors on AIDS defining events and hospitalisations in 10 French AIDS reference centres
5. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France 1995-1995
6. The changing pattern of hospital admissions to a London Hospital of patients with HIV: 1988-1997
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less
8. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
9. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection
10. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
11. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
12. Predictors of virological success and ensuing failure among HIV+ patients starting HAART in Europe: Results from the EuroSIDA study
13. Human immunodeficiency virus 1 protease inhibitors in clinical practise
14. Virological failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
15. Virological response to protease inhibitor therapy in an HIV clinic cohort
16. CD4 cell count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
17. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort
18. HIV-1 protease inhibitors. A review for clinicians
19. Potential factors affecting adherence with HIV therapy
20. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
21. 1998 Revision to the British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals
22. Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-1997
23. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART and survival
24. Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care?
25. Analysis of HIV-1 clinical trials: Statistical magic?
26. HIV-protease inhibitors
27. New antiretrovirals and new combinations
28. Has the spectrum of AIDS-defining illnesses been changing since the introduction of new treatments and combinations of treatments
29. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral therapy
30. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
31. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy